The transmembrane protease serine (TMPRSS3/TADG-12) D variant: A potential candidate for diagnosis and therapeutic intervention in ovarian cancer

Tumor Biology

Volumn 25, Issue 3, 2004, Pages 141-148

  Sawasaki, Takashi ^a   Shigemasa, Kazushi ^b   Gu, Lijun ^b   Beard, John B ^a   O'Brien, Timothy J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

nRNA; Ovarian cancer; Overexpression; Semiquantitative PCR; TMPRSS3 TADG 12D variant

Indexed keywords

MEMBRANE ENZYME; MESSENGER RNA; PROTEIN TADG 12D; SERINE PROTEINASE; TUMOR MARKER; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; TADG 12 SERINE PROTEASE; TADG-12 SERINE PROTEASE; TMPRSS3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADENOMA; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG TARGETING; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVARY; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; RNA ANALYSIS; AMINO ACID SEQUENCE; BIOSYNTHESIS; CARCINOMA; CELL TRANSFORMATION; COLLOID CARCINOMA; GENE EXPRESSION PROFILING; GENETICS; MOLECULAR GENETICS;

ADENOCARCINOMA, MUCINOUS; ADENOMA; AMINO ACID SEQUENCE; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 4644309151     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079146     Document Type: Article

References (33)

1. Neurath H: The diversity of proteolytic enzymes; in Beynon RJ, Bond JS (ed): Proteolytic Enzymes. Oxford, IRL Press, 1989, pp 1-13.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-336.
3. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155.
4. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-217.
5. Hooper JD, Clements JA, Quigley JP, Antalis TM: Type II transmembrane serine proteases. J Biol Chem 2001;276:857-860.
6. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002;19:193-207.
7. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ: Hepsin, a cell surface serine protease identified in hepatoma cells is overexpressed in ovarian cancer. Cancer Res 1997;57:2884-2887.
8. Shigemasa K, Underwood LJ, Beard J, Tanimoto H, Ohama K, Parmley TH, O'Brien TJ: Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J Soc Gynecol Invest 2000;7:358-362.
9. Underwood LJ, Shigemasa K, Tanimoto H, Beard JB, Schneider EN, Wang Y, Parmley TH, O'Brien TJ: Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta 2000;1502:337-350.
10. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumor Biol 2001;22:103-114.
11. Scott HS, Kudoh J, Wattenhofer M, Shibuya K, Berry A, Chrast R, Guipponi M, Wang J, Kawasaki K, Asakawa S, Minoshima S, Younus F, Mehdi SQ, Radhakrishna U, Papasavvas MP, Gehrig C, Rossier C, Korostishevsky M, Gal A, Shimizu N, Bonne-Tamir B, Antonarakis SE: Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet 2001;27:59-63.
12. Early P, Rogers J, Davis M, Calame K, Bond M, Wall R, Hood L: Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell 1980;20:313-319.
13. Nagoshi RN, McKeown M, Burtis KC, Belote JM, Baker BS: The control of alternative splicing at genes regulating sexual differentiation in D. melanogaster. Cell 1988;53/2:229-236.
14. Modrek B, Resch A, Grasso C, Lee C: Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001;29:2850-2859.
15. Brett D, Hanke J, Lehmann G, Haase S, Delbruck S, Krueger S, Reich J, Bork P: EST comparison indicates 38% of human mRNAs contain possible alternative splice forms. FEBS Lett 2000;474:83-86.
16. Mironov AA, Fickett JW, Gelfand MS: Frequent alternative splicing of human genes. Genome Res 1999;9:1288-1293.
17. Xie H, Zhu WY, Wasserman A, Grebinskiy V, Olson A, Mintz L: Computational analysis of alternative splicing using EST tissue information. Genomics 2002;80:326-330.
18. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R: Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002;8:2253-2259.
19. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002;62:3289-3297.
20. Lee MP, Feinberg AP: Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997;57:3131-3134.
21. Wang Z, Lo HS, Yang H, Gere S, Hu Y, Buetow KH, Lee MP: Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 2003;63:655-657.
22. Russel P: Surface epithelial-stromal tumors of the ovary; in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract. New York, Springer, 1995, pp 705-782.
23. Benedet JL, Bender H, Jones H 3rd, Ngan HYS, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262.
24. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 1996;46:5-27.
25. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ: Increased expression of protease M in ovarian tumors. Tumor Biol 2001;22:11-18.
26. Tanimoto H, Underwood LJ, Shigemasa K, Yan Y, Clarke J, Parmley TH, O'Brien TJ: The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-2082.
27. Shigemasa K, Tanimoto H, Underwood LJ, Parmley TH, Arihiro K, Ohama K, O'Brien TJ: Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer 2001;11:454-461.
28. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ: Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 1999;59:4435-4439.
29. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204.
30. Diamandis EP, Yousef GM: Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem 2002;48:1198-1205.
31. Hung YC, Ueda M, Terai Y, Kumagai K, Ueki K, Kanda K, Ymaguchi H, Akise D, Ueki M: Homobox gene expression and mutation in cervical carcinoma cells. Cancer Sci 2003;94:437-441.
32. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PDP, Luben BA, Easton F, Ponder BA: Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-193.
33. Angelopoulou K, Diamandis EP: Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: Application to breast and ovarian tumors. J Clin Lab Anal 1998;12/4:250-256.